Home Cart Sign in  
Chemical Structure| 50-63-5 Chemical Structure| 50-63-5

Structure of Chloroquine phosphate
CAS No.: 50-63-5

Chemical Structure| 50-63-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Chloroquine phosphate is an antimalarial and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. It is an autophagy and toll-like receptor (TLR) inhibitor and is highly effective in controlling SARS-CoV-2 (COVID-19) infection in vitro (EC50 = 1.13 μM).

Synonyms: Chloroquine(phosphate)(CRM); Chloroquine diphosphate; NSC 14050

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations

Perez, Celia N. ; Falcon, Cristian R. ; Mons, Johinna Delgado ; Orlandi, Federico Cuello ; Sangiacomo, Mercedes ; Fernandez-Munoz, Juan M. , et al.

Abstract: Over the last years, the incidence of melanoma, the deadliest form of skin cancer, has risen significantly. Nearly half of the melanoma patients exhibit the BRAFV600E mutation. Although the use of BRAF and MEK inhibitors (BRAFi and MEKi) showed an impressive success rate in melanoma patients, durability of response remains an issue because tumor quickly becomes resistant. Here, we generated and characterized Lu1205 and A375 melanoma cells resistant to vemurafenib (BRAFi). Resistant cells (Lu1205R and A375R) exhibit higher IC50 (5-6 fold increase) and phospho-ERK levels and 2-3 times reduced apoptosis than their sensitive parents (Lu1205S and A375S). Moreover, resistant cells are 2-3 times bigger, display a more elongated morphol. and have a modulation of migration capacity. Interestingly, pharmacol. inhibition of sphingosine kinases, that prevents sphingosine-1-phosphate production, reduces migration of Lu1205R cells by 50%. In addition, although Lu1205R cells showed increased basal levels of the autophagy markers LC3II and p62, they have decreased autophagosome degradation and autophagy flux. Remarkably, expression of Rab27A and Rab27B, which are involved in the release of extracellular vesicles are dramatically augmented in resistant cells (i.e. 5-7 fold increase). Indeed, conditioned media obtained from Lu1205R cells increased the resistance to vemurafenib of sensitive cells. Hence, these results support that resistance to vemurafenib modulates migration and the autophagic flux and may be transferred to nearby sensitive melanoma cells by factors that are released to the extracellular milieu by resistant cells.

Keywords: Melanoma ; BRAF V600E mutation ; Vemurafenib ; Autophagy ; Resistance transfer

Purchased from AmBeed:

Alternative Products

Product Details of Chloroquine phosphate

CAS No. :50-63-5
Formula : C18H32ClN3O8P2
M.W : 515.86
SMILES Code : CC(NC1=CC=NC2=CC(Cl)=CC=C12)CCCN(CC)CC.O=P(O)(O)O.O=P(O)(O)O
Synonyms :
Chloroquine(phosphate)(CRM); Chloroquine diphosphate; NSC 14050
MDL No. :MFCD00069852
InChI Key :QKICWELGRMTQCR-UHFFFAOYSA-N
Pubchem ID :64927

Safety of Chloroquine phosphate

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Related Pathways of Chloroquine phosphate

DNA
PI3K-AKT

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
HK-2 cells 10 μM 24 h CQ remarkably reversed the nilotinib-induced decrease in MMP and inhibited nilotinib-induced intracellular ROS accumulation. Adv Sci (Weinh). 2023 Sep;10(26):e2302002.
HUVECs 10 μM 24 h CQ remarkably reversed the nilotinib-induced decrease in MMP and inhibited nilotinib-induced intracellular ROS accumulation. Adv Sci (Weinh). 2023 Sep;10(26):e2302002.
WS hMSCs 0.2-100 μM Chloroquine at low concentrations (0.2-5 μM) promoted cell self-renewal, while higher concentrations (20 μM and above) inhibited cell proliferation. Treatment with 1 μM CQ decreased the percentage of SA-β-gal-positive cells and increased the number of Ki67-positive cells, while also reducing IL-6 secretion. Protein Cell. 2022 Jun;13(6):454-461.
U2OS cells 10, 20, 40 μM 16 h Induced eIF2α phosphorylation Cell Death Dis. 2021 Jan 6;12(1):6.
U2OS-GFP-LC3 ATG5 knockout cells 10, 20, 40 μM 6 h ATG5 knockout cells failed to accumulate autophagosomes Cell Death Dis. 2021 Jan 6;12(1):6.
U2OS-GFP-LC3 wild type cells 10, 20, 40 μM 6 h Induced GFP-LC3 dot formation, indicating autophagosome accumulation Cell Death Dis. 2021 Jan 6;12(1):6.
Human glioma H4 cells 10, 20, 40 μM 6 h Induced GFP-LC3 dot formation, indicating autophagosome accumulation Cell Death Dis. 2021 Jan 6;12(1):6.
Human U2OS osteosarcoma cells 10, 20, 40 μM 6 h Induced GFP-LC3 dot formation, indicating autophagosome accumulation Cell Death Dis. 2021 Jan 6;12(1):6.
lymphoblastoid cells 100 μM Chloroquine induced phosphorylation of KAP1 at S824 and ZEBRA expression, and the EBV lytic cycle reached completion, releasing substantial numbers of viral particles. PLoS Pathog. 2017 Mar 1;13(3):e1006249.
Jijoye and Raji Burkitt lymphoma cells 200 μM Chloroquine induced the expression of ZEBRA in both cell lines, although with different temporal patterns. PLoS Pathog. 2017 Mar 1;13(3):e1006249.
Calu-3 cells 64.7 µM Inhibit SARS-CoV-2 infection J Mol Cell Biol. 2021 Jul 6;13(3):175-184.
Vero E6 cells 6.5 µM Inhibit SARS-CoV-2 infection J Mol Cell Biol. 2021 Jul 6;13(3):175-184.
HH514-16 Burkitt lymphoma cells 200 μM 24 h Chloroquine induced phosphorylation of KAP1 at S824 and activated the EBV lytic cycle. PLoS Pathog. 2017 Mar 1;13(3):e1006249.
MiaPaca-2 100 μM 72 h To evaluate the cytotoxicity of CQ-HES, results showed that CQ-HES had similar cytotoxicity to HCQ. Biomacromolecules. 2017 Aug 14;18(8):2247-2257.
MiaPaca-1 100 μM 72 h To evaluate the cytotoxicity of CQ-HES, results showed that CQ-HES had similar cytotoxicity to HCQ. Biomacromolecules. 2017 Aug 14;18(8):2247-2257.
AsPC-1 100 μM 72 h To evaluate the cytotoxicity of CQ-HES, results showed that CQ-HES had similar cytotoxicity to HCQ. Biomacromolecules. 2017 Aug 14;18(8):2247-2257.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6J mice Nilotinib-induced nephrotoxicity model Oral 30 mg/kg Daily for 30 days HCQ significantly reversed the nilotinib-induced elevation of BUN and Scr and ameliorated kidney cell apoptosis and oxidative stress induced by nilotinib. Adv Sci (Weinh). 2023 Sep;10(26):e2302002.
Sprague Dawley (SD) rats Physiologically aged rat model Oral 0.1 mg/kg Twice a week for 5 months Low-dose CQ treatment extended the lifespan of rats, repressed systemic inflammation, and inhibited fibrosis across multiple tissues. Furthermore, CQ treatment mitigated age-related molecular changes and repressed genes linked to fibrosis and the inflammatory response. Protein Cell. 2022 Jun;13(6):454-461.
Mice C57Bl/6j mice Intraperitoneal injection 50 mg/kg Once daily for 10 days Induced eIF2α phosphorylation Cell Death Dis. 2021 Jan 6;12(1):6.
Mice HCoV-OC43 infection model 15 mg/kg Prevent HCoV-OC43 infection J Mol Cell Biol. 2021 Jul 6;13(3):175-184.

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02563496 Malaria, Vivax Phase 2 Recruiting November 30, 2019 Colombia ... More >> GSK Investigational Site Recruiting Monteria, Colombia Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com    Contact: EU GSK Clinical Trials Call Center    +44 (0) 20 8990 4466    GSKClinicalSupportHD@gsk.com    Thailand GSK Investigational Site Not yet recruiting Tak, Thailand, 63110 Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com    Contact: EU GSK Clinical Trials Call Center    +44 (0) 20 8990 4466    GSKClinicalSupportHD@gsk.com    Vietnam GSK Investigational Site Recruiting Hanoi, Vietnam, 100000 Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com    Contact: EU GSK Clinical Trials Call Center    +44 (0) 20 8990 4466    GSKClinicalSupportHD@gsk.com    GSK Investigational Site Recruiting Ho Chi Minh City, Vietnam, 700000 Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com    Contact: EU GSK Clinical Trials Call Center    +44 (0) 20 8990 4466    GSKClinicalSupportHD@gsk.com    GSK Investigational Site Recruiting Ho Chi Minh, Vietnam Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com    Contact: EU GSK Clinical Trials Call Center    +44 (0) 20 8990 4466    GSKClinicalSupportHD@gsk.com Less <<
NCT01136850 Malaria in Pregnancy ... More >> Sexually Transmitted Infections Anaemia Less << Phase 3 Completed - Papua New Guinea ... More >> Papua New Guinea Institute of Medical Research Madang, Madang Province, Papua New Guinea Less <<
NCT00157859 Falciparum Malaria ... More >> Vivax Malaria Less << Not Applicable Completed - Indonesia ... More >> SP9 & SP12 Public Health- Malaria control clinics Timika, Papua, Indonesia Less <<
NCT01662700 Acute Uncomplicated Malaria Wi... More >>th P.Vivax Infection Less << Phase 4 Unknown December 2014 Thailand ... More >> Kraburi Hospital Recruiting Ranong, Thailand Contact: Thongchai Keeratihatayagorn, MD    +6681 8952244       Contact: Prakaykaew Charunwatthana, MD    +6681-844 9678    jib@tropmedres.ac    Sub-Investigator: Thongchai Keeratihatayagorn, MD          Khunhan Hospital Recruiting Srisaket, Thailand Contact: Ratchadaporn Runchareon, MD    +6681-790-9275       Contact: Prakaykaew Charunwatthana, MD    +6681-844 9678    jib@tropmedres.ac    Sub-Investigator: Ratchadaporn Runchareon, MD          Phusing Hospital Recruiting Srisaket, Thailand Contact: Kitipumi Chutasmit, MD    +6687 9654139       Contact: Prakaykaew Charunwatthan, MD    +6681-844 9678    jib@tropmedres.ac    Sub-Investigator: Kitipumi Chutasmit, MD          Kap Choeng Hospital Recruiting Surin, Thailand Contact: Satawat Sinprasitkul, MD    +6681 7601087       Contact: Prakaykaew Charunwatthana, MD    +6681-844 9678    jib@tropmedres.ac    Sub-Investigator: Satawat Sinprasitkul, MD          Sub-Investigator: Worawun Kopkitngam, MD Less <<
NCT02058173 Hepatitis C Virus Phase 4 Completed - Iran, Islamic Republic of ... More >> Health Policy Research Center Shiraz, Fars, Iran, Islamic Republic of Less <<
NCT01680406 Plasmodium Vivax Infection Phase 4 Completed - Ethiopia ... More >> Bishoftu Malaria Center Debre Zeit, Ethiopia Batu Health Center Zeway, Ethiopia Less <<
NCT01052584 Malaria Not Applicable Completed - Ethiopia ... More >> DebreZeit Malaria Center Debrezeit, Oromia, Ethiopia Bulbula Health Center Zeway, Oromia, Ethiopia Less <<
NCT02773979 Plasmodium Falciparum Infectio... More >>n Less << Phase 1 Completed - United States, Washington ... More >> Kaiser Permanente Washington Health Research Institute - Vaccines and Infectious Diseases Seattle, Washington, United States, 98101-1466 Less <<
NCT00964691 Malaria Malar... More >>ia in Pregnancy Less << Phase 4 Terminated(Low prevalence of m... More >>alaria, high prevalence of reported allergy to sulphur drugs, high proportion of women not meeting the inclusion criterea.) Less << August 2010 Solomon Islands ... More >> Honiara City Council Honiara, Solomon Islands Less <<
NCT03337152 Malaria, Vivax ... More >> G6PD Deficiency Less << Phase 4 Suspended(study met study halt... More >>ing rules) Less << December 31, 2018 Thailand ... More >> Shoklo Malaria Research Unit (SMRU) Mae Sot, Thailand Less <<
NCT00399074 Sickle Cell Anemia ... More >> Malaria Less << Phase 3 Completed - Uganda ... More >> Mulago Hospital Kampala, Central, Uganda, 256 Less <<
NCT00084227 Malaria, Falciparum Phase 2 Phase 3 Completed - -
NCT03400865 Resistance, Disease ... More >> Prolactinoma Less << Not Applicable Not yet recruiting December 30, 2020 China, Beijing ... More >> Beijing Tiantan Hospital Not yet recruiting Beijing, Beijing, China China, Shanghai Huashan Hospital Not yet recruiting Shanghai, Shanghai, China, 200025 Ruijin Hosipital Enrolling by invitation Shanghai, Shanghai, China, 200025 China Chinese PLA General Hospital Not yet recruiting Beijing, China Peking Union Medical College Hospital Recruiting Beijing, China Xinqiao Hospital of Chongqing Not yet recruiting Chongqing, China First Affiliated Hospital of Fujian Medical Recruiting Fujian, China First Hospital of China Medical University Not yet recruiting Shenyang, China First Affiliated Hospital of Wenzhou Medical Univeristy Recruiting Wenzhou, China Less <<
NCT00486694 Malaria, Vivax Phase 2 Completed - -
NCT03243461 Glioblastoma WHO Grade IV ... More >> Diffuse Midline Glioma Histone 3 K27M WHO Grade IV Anaplastic Astrocytoma WHO Grade III Diffuse Intrinsic Pontine Glioma Gliomatosis Cerebri Less << Phase 3 Recruiting June 1, 2023 Germany ... More >> Klinikum Augsburg Recruiting Augsburg, Germany Contact: Michael Frühwald, Prof.          Evangelisches Krankenhaus Bielefeld Recruiting Bielefeld, Germany Contact: Norbert Jorch, Dr.          Universitätsklinikum Bonn Recruiting Bonn, Germany Contact: Carola Weber, Dr.          Klinikum Bremen-Mitte gGmbH Recruiting Bremen, Germany Contact: Arnulf Pekrun, Prof.          Klinikum Chemnitz gGmbH Recruiting Chemnitz, Germany Contact: André Hofmann, Dr.          Carl-Thiem-Klinikum Cottbus gGmbH Recruiting Cottbus, Germany Contact: Georg Schwabe, PD Dr.          Sana Kliniken Duisburg GmbH - Wedau Kliniken Recruiting Duisburg, Germany Contact: Tanja Höll, Dr.          Universitätsklinikum Erlangen Recruiting Erlangen, Germany Contact: Markus Metzler, Prof.          Universitätsklinikum Freiburg Recruiting Freiburg, Germany Contact: Charlotte Niemeyer, Prof.          Universitätsmedizin Greifswald Recruiting Greifswald, Germany Contact: Holger Lode, Prof.          Universitätsmedizin Göttingen Recruiting Göttingen, Germany Contact: Christof Kramm, Prof.          Universitätsklinikum Halle Recruiting Halle, Germany Contact: Toralf Bernig, Dr.          Universitätsklinikum des Saarlandes Recruiting Homburg, Germany Contact: Norbert Graf, Prof.          Gesundheit Nordhessen - Klinikum Kassel Recruiting Kassel, Germany Contact: Michaela Nathrath, Prof.          Universitätsklinikum Leipzig Recruiting Leipzig, Germany Contact: Holger Christiansen, Prof.          UMM Universitätsmedizin Mannheim Recruiting Mannheim, Germany Contact: Matthias Dürken, PD Dr.          Johannes Wesling Klinikum Minden Recruiting Minden, Germany Contact: Bernhard Erdlenbruch, Prof.          Universitätsklinikum Münster Recruiting Münster, Germany Contact: Ronald Sträter, PD Dr.          Klinikum Oldenburg gGmbH Recruiting Oldenburg, Germany Contact: Hermann Müller, Prof.          Universitätsklinikum Regensburg Recruiting Regensburg, Germany Contact: Marcus Jakob, Dr.          ASKLEPIOS Klinik St. Augustin Recruiting Sankt Augustin, Germany Contact: Harald Reinhard, PD Dr.          Klinikum Stuttgart - Olgahospital Recruiting Stuttgart, Germany Contact: Stefan Bielack, Prof.          Universitätsklinikum Tübingen Recruiting Tübingen, Germany Contact: Martin Ebinger, PD Dr. Less <<
NCT01728701 Malaria Plasm... More >>odium Falciparum Less << Phase 1 Completed - Netherlands ... More >> Radboud University Nijmegen Medical Centre Nijmegen, Netherlands, 6500 HB Less <<
NCT01783340 Malaria, Falciparum Phase 1 Phase 2 Withdrawn(No funding) April 2014 Netherlands ... More >> Leiden University Medical Centre Leiden, Netherlands, 2333ZA Less <<
NCT03610399 P Vivax Malar... More >>ia, Vivax Less << Not Applicable Recruiting July 1, 2019 Brazil ... More >> Hospital do Jurua Recruiting Cruzeiro do Sul, Brazil Contact: Suiane Negreiros, MD       omsvalle@hotmail.com    Principal Investigator: Suiane Negreiros, MD Less <<
NCT01236612 Plasmodium Falciparum Malaria Not Applicable Completed - Netherlands ... More >> Radboud University Nijmegen Medical Centre Nijmegen, Netherlands, 6500 HB Less <<
NCT03208907 Malaria, Vivax ... More >> Therapeutics Less << Phase 3 Not yet recruiting December 2020 -
NCT00084240 Malaria, Falciparum Phase 2 Phase 3 Terminated(See Detailed Descri... More >>ption) Less << - -
NCT02394197 Malaria Phase 4 Completed - -
NCT01218893 Plasmodium Falciparum Malaria Not Applicable Completed - Netherlands ... More >> Leiden University Medical Centre Leiden, Netherlands, 2300 RC Less <<
NCT00132535 Malaria in Pregnancy ... More >> HIV Infections Less << Not Applicable Completed - Uganda ... More >> Uganda AIDS Commission Kampala, Uganda, P.O. Box 10779 Less <<
NCT01103063 - Terminated(See termination rea... More >>son in detailed description.) Less << - -
NCT01103063 Intermittent Preventive Treatm... More >>ent In Pregnancy (IPTp) Less << Phase 3 Terminated(See termination rea... More >>son in detailed description.) Less << - Benin ... More >> Centre de Santé d'AHOUANSORI-AGUE Cotonou, Benin Hôpital Bethesda Cotonou, Benin Kenya Siaya District Hospital Siaya, Kenya Malawi Zomba Central Hospital Zomba, Malawi Tanzania Teule Hospital Muheza, Tanga, Tanzania Bugando Medical Centre Mwanza, Tanzania, 1903 Nyamagana District Hospital, c/o National Institute for Medical Research, Mwanza Centre Mwanza, Tanzania Nyamagana District Hospital Mwanza, Tanzania Uganda Mulago Hospital Complex Kampala, Uganda Less <<
NCT00082576 Malaria, Falciparum Phase 2 Phase 3 Completed - Ghana ... More >> Pfizer Investigational Site Navrongo, Ghana Mali Pfizer Investigational Site Bamako, Mali Uganda Pfizer Investigational Site Jinja, Uganda Pfizer Investigational Site Kampala, Uganda Zambia Pfizer Investigational Site Ndola, Zambia Less <<
NCT00455403 Metabolic Syndrome X ... More >> Overweight Hypertension Dyslipidemias Prediabetic State Less << Not Applicable Active, not recruiting December 2019 United States, Missouri ... More >> Washington University School of Medicine Saint Louis, Missouri, United States, 63110 Less <<
NCT00229775 Malaria Not Applicable Completed - Philippines ... More >> Kalinga Health Center Tabuk, Kalinga Province, Philippines Davao Health Center Davao City, Mindinao, Philippines Palawan Health Center Puerto Princesa, Palawan, Philippines Less <<
NCT02550964 - Recruiting January 2019 Korea, Republic of ... More >> Asan Medical Center Recruiting Seoul, Korea, Republic of, 05505 Contact: JooYong Lee, Professor    +82-2-3010-3976    ophthalmo@amc.seoul.kr Less <<
NCT00158548 Malaria Falci... More >>parum Malaria Vivax Malaria Less << Phase 3 Completed - Pakistan ... More >> HealthNet International Peshawar, Pakistan Less <<
NCT01446016 Breast Neoplasms ... More >> Breast Cancer Less << Phase 2 Recruiting August 1, 2019 United States, Texas ... More >> Houston Methodist Hospital Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Cancer Center Research    713-441-0629    ccresearch@houstonmethodist.org    Principal Investigator: Jenny Chang, MD          Sub-Investigator: Angel A. Rodriguez, MD          Sub-Investigator: Daniel Lehane, MD          Sub-Investigator: Monisha Singh, MD          Sub-Investigator: Tejal Patel, MD          Sub-Investigator: Jorge Darcourt, MD          Houston Methodist Hospital Willowbrook Recruiting Houston, Texas, United States, 77070 Contact: Houston Methodist Cancer Center    713-441-0629    ccresearch@houstonmethodist.org    Principal Investigator: Anna Belcheva, MD          Houston Methodist Hospital Sugar Land Recruiting Sugar Land, Texas, United States, 77479 Contact: Houston Methodist Cancer Center    713-441-0629    ccresearch@houstonmethodist.org    Principal Investigator: Jorge Darcourt, MD Less <<
NCT01422954 Malaria Plasm... More >>odium Falciparum Less << Not Applicable Completed - Netherlands ... More >> Leiden University Medical Centre Leiden, Netherlands, 2333 ZA Less <<
NCT00074841 PLASMODIUM FALCIPARUM MALARIA Phase 2 Phase 3 Completed - India ... More >> Pfizer Investigational Site Dispur Guwahati, Assam, India, 781006 Pfizer Investigational Site Bambolim, Gao, India, 403002 Pfizer Investigational Site Nagpur, Maharashtra, India, 440 018 Pfizer Investigational Site Parel Mumbai, Maharashtra, India, 400012 Pfizer Investigational Site Rourkela, Orissa, India, 769005 Pfizer Investigational Site Vellore, Tamil Nadu, India, 632 004 Pfizer Investigational Site Indore, India, 452001 Less <<
NCT01178021 Vivax Malaria Phase 4 Unknown December 2014 Afghanistan ... More >> Provincial Malaria Control Centers (MRC) Recruiting Maimana, Faryab, Afghanistan Contact: Ghulam Rahim Awab, MD       awabgr@yahoo.com    Principal Investigator: Ghulam Rahim Awab, MD          Provincial Malaria Control Centers (MRC) Recruiting Jalalabad, Afghanistan Contact: Ghulam Rahim Awab, MD          Principal Investigator: Ghulam Rahim Awab, MD          Provincial Malaria Control Centers (MRC) Recruiting Kunduz, Afghanistan Contact: Ghulam Rahim Awab, MD          Principal Investigator: Ghulam Rahim Awab, MD Less <<
NCT00137514 Malaria, Falciparum Phase 4 Completed - Guinea-Bissau ... More >> Bandim Health Project Apartado 861, Bissau, Guinea-Bissau Less <<
NCT00442403 Malaria Phase 3 Suspended(At the end of the ye... More >>ar 2002, Cameroon switched from chloroquine to amodiaquine as first-line therapy for of uncomplicated malaria.) Less << - Cameroon ... More >> Institute of Medical Research and study of Medicinal Plants, Medical Research Center Yaounde, Cameroon Less <<
NCT01378286 Malaria Phase 3 Completed - Brazil ... More >> Administrative office Sao Paulo, Brazil Less <<
NCT01366235 Healthy Volunteers Phase 1 Completed - Korea, Republic of ... More >> Asan Medical Center Seoul, Korea, Republic of Less <<
NCT01107145 Plasmodium Vivax Malaria Phase 4 Terminated(Extremely slow enro... More >>llment) Less << - Brazil ... More >> Hospital Geral Maternidade de Cruzeiro do Sul Cruzeiro do Sul, Acre, Brazil Hospital Municipal Teonila Alves Anajas, Para, Brazil Centro de Pesquisa em Patologias Tropicais Porto Velho, Rondonia, Brazil Less <<
NCT00391313 Chikungunya Virus Phase 3 Terminated(Terminated Chikungu... More >>nya diseases has regressed and no more patients was suffering) Less << - France ... More >> Cellule Coordination Nivachik Saint Pierre, ile de la Reunion, France, 97400 Less <<
NCT00677833 - Completed - -
NCT01074905 Vivax Malaria Phase 3 Completed - Thailand ... More >> Shoklo Malaria Research Unit Mae Sot, Thailand Less <<
NCT00805519 Osteoarthritis of the Knee Phase 4 Completed - Iran, Islamic Republic of ... More >> ArdabiUMS Clinic of Rheumatology Ardabil, Iran, Islamic Republic of, 56197 Less <<
NCT00082563 Malaria, Falciparum Phase 2 Terminated - -
NCT00677833 Malaria, Falciparum Phase 2 Phase 3 Completed - Burkina Faso ... More >> Pfizer Investigational Site Nouna, Burkina Faso Pfizer Investigational Site Ouagadougou 01, Burkina Faso Pfizer Investigational Site Ouagadougou, Burkina Faso Côte D'Ivoire Pfizer Investigational Site Abidjan 13, Côte D'Ivoire Ghana Pfizer Investigational Site Navrongo, Ghana Kenya Pfizer Investigational Site Kisumu, Kenya, 40100 Mali Pfizer Investigational Site Bamako, West Africa, Mali Pfizer Investigational Site Sikasso, West Africa, Mali Less <<
NCT00455325 Metabolic Syndrome X ... More >> Overweight Hypertension Dyslipidemias Prediabetic State Less << Phase 2 Active, not recruiting January 2019 United States, Missouri ... More >> Washington University in St. Louis Saint Louis, Missouri, United States, 63110 Less <<
NCT00290420 Malaria Phase 4 Withdrawn(important delays and... More >> malaria season missed, due to political changes) Less << November 2007 -
NCT00125489 Malaria Plasm... More >>odium Falciparum Malaria Less << Phase 4 Completed - Malawi ... More >> Blantyre Malaria Project Blantyre, Malawi Less <<
NCT00849602 Dengue Phase 1 Phase 2 Unknown June 2009 Brazil ... More >> São Paulo University Medical School at Ribeirão Preto Ribeirão Preto, SP, Brazil, 14048.900 Less <<
NCT00224978 Glioblastoma Multiforme Phase 3 Completed - Mexico ... More >> National Institute of Neurology and Neurosurgery Mexico City, Mexico, 14269 Less <<
NCT00282919 - Completed - -
NCT00379821 Plasmodium Falciparum Infectio... More >>n Less << Phase 3 Completed - Malawi ... More >> Blantyre Malaria Project - Ndirande Health Centre Blantyre, Malawi Less <<
NCT00282919 Falciparum Malaria Phase 2 Completed - Colombia ... More >> Pfizer Investigational Site San Andres de Tumaco, Narino, Colombia India Pfizer Investigational Site Bambolim, Goa, India, 403002 Less <<
NCT00426439 Malaria, Falciparum Phase 4 Completed - Guinea-Bissau ... More >> Bandim Health Project Apartado 861, Bissau, Guinea-Bissau Less <<
NCT00379821 - Completed - -
NCT02043652 - Completed - -
NCT03278808 Malaria Phase 2 Recruiting September 1, 2020 United States, Maryland ... More >> Clinical Research Unit, Uniformed Services University of Health Sciences Not yet recruiting Bethesda, Maryland, United States, 20814 Contact: Thomas Oliver, MD    301-295-0016    thomas.g.oliver.mil@mail.mil    WRAIR Recruiting Silver Spring, Maryland, United States, 20910 Contact: Jeffrey R Livezey, MD    301-319-3217    jeffrey.r.livezey.mil@mail.mil Less <<
NCT00819390 HIV Infections Phase 2 Completed - United States, Alabama ... More >> Alabama Therapeutics CRS (5801) Birmingham, Alabama, United States, 35294 United States, California Ucsd, Avrc Crs (701) San Diego, California, United States, 92103 United States, Colorado University of Colorado Hospital CRS (6101) Aurora, Colorado, United States, 80045 United States, District of Columbia Georgetown University CRS (GU CRS) (1008) Washington, District of Columbia, United States, 20007 United States, Maryland Johns Hopkins Adult AIDS CRS (201) Baltimore, Maryland, United States, 21205 United States, Massachusetts Massachusetts General Hospital ACTG CRS (101) Boston, Massachusetts, United States, 02114 United States, Missouri Washington University CRS (2101) St. Louis, Missouri, United States, 63110 United States, New York Cornell CRS (7804) New York, New York, United States, 10011 United States, North Carolina Unc Aids Crs (3201) Chapel Hill, North Carolina, United States, 27514 United States, Ohio Univ. of Cincinnati CRS (2401) Cincinnati, Ohio, United States, 45267 Case CRS (2501) Cleveland, Ohio, United States, 44106 MetroHealth CRS (2503) Cleveland, Ohio, United States, 44109 United States, Pennsylvania Hosp. of the Univ. of Pennsylvania CRS (6201) Philadelphia, Pennsylvania, United States, 19104 Pittsburgh CRS (1001) Pittsburgh, Pennsylvania, United States, 15213 United States, Tennessee Vanderbilt Therapeutics CRS (3652) Nashville, Tennessee, United States, 37204 Less <<
NCT00323375 Malaria Phase 1 Completed - United States, Louisiana ... More >> Tulane-LSU-Charity Hospital General Clinical Research Center New Orleans, Louisiana, United States, 70112 Less <<
NCT01640574 Vivax Malaria Phase 3 Completed - Thailand ... More >> Shoklo Malaria Research Unit Mae Sot, Tak, Thailand, 63110 Less <<
NCT02043652 Malaria Not Applicable Completed - Brazil ... More >> Hospital do Jurua Cruzeiro do Sul, Brazil Less <<
NCT01218932 Vivax Malaria Phase 1 Completed - Thailand ... More >> Hospital For Tropical Diseases Bangkok, Thailand Less <<
NCT02348788 Plasmodium Vivax Malaria Witho... More >>ut Complication Less << Phase 3 Recruiting December 2017 Malaysia ... More >> Kota Marudu District Hospital Recruiting Kota Marudu, Sabah, Malaysia Contact: Matthew Grigg, MBBS    +60149569476    mat_grigg@hotmail.com    Principal Investigator: Timothy William, MBBS          Sub-Investigator: Tsin W Yeo, MBBS          Sub-Investigator: Nicholas M Anstey, MBBS          Sub-Investigator: Bridget E Barber, MBBS          Sub-Investigator: Jayaram Menon, MBBS          Sub-Investigator: Ric N Price, MBBS          Sub-Investigator: Matthew J Grigg, MBBS          Kudat District Hospital Recruiting Kudat, Sabah, Malaysia Contact: Matthew Grigg, MBBS    +60149569476    mat_grigg@hotmail.com    Sub-Investigator: Tsin W Yeo, MBBS          Sub-Investigator: Nicholas M Anstey, MBBS          Sub-Investigator: Bridget E Barber, MBBS          Sub-Investigator: Prabakaran Dhanaraj, MBBS          Sub-Investigator: Jayaram Menon, MBBS          Sub-Investigator: Ric N Price, MBBS          Principal Investigator: Timothy William, MBBS          Sub-Investigator: Matthew J Grigg, MBBS          Pitas District Hospital Recruiting Pitas, Sabah, Malaysia Contact: Matthew Grigg, MBBS    +60149569476    mat_grigg@hotmail.com    Principal Investigator: Timothy William, MBBS          Sub-Investigator: Tsin W Yeo, MBBS          Sub-Investigator: Nicholas M Anstey, MBBS          Sub-Investigator: Bridget E Barber, MBBS          Sub-Investigator: Jayaram Menon, MBBS          Sub-Investigator: Ric N Price, MBBS          Sub-Investigator: Matthew J Grigg, MBBS Less <<
NCT00367653 Malaria Phase 3 Completed - Burkina Faso ... More >> Pfizer Investigational Site Ouagadougou, West Africa, Burkina Faso, 01 Pfizer Investigational Site Nouna, Burkina Faso Ghana Pfizer Investigational Site Navrongo, West Africa, Ghana Kenya Pfizer Investigational Site Kisumu, Kenya, 40100 Mali Pfizer Investigational Site Bamako, West Africa, Mali Pfizer Investigational Site Bamako, Mali Senegal Pfizer Investigational Site Senegal, West Africa, Senegal Zambia Pfizer Investigational Site Ndola, Zambia Less <<
NCT00819390 - Completed - -
NCT02432417 Glioblastoma ... More >>Astrocytoma, Grade IV Less << Phase 2 Not yet recruiting January 2024 -
NCT01443130 Malaria Phase 3 Completed - Malawi ... More >> Blantyre Malaria Project - Queen Elizabeth Central Hospital Blantryre, Blantyre, Malawi Less <<
NCT01019408 Malaria, Falciparum Phase 4 Completed - Pakistan ... More >> Adezai Basic Health Unit Adezai, Nwfp, Pakistan Baghicha Basic Health Unit Baghicha, Nwfp, Pakistan Kagan Basic Health Unit Kagan, Nwfp, Pakistan Less <<
NCT01438177 Multiple Myeloma Phase 2 Terminated(PI left institution... More >>.) Less << - United States, New York ... More >> NYU Cancer Institute New York, New York, United States, 10016 Less <<
NCT02192944 Healthy Phase 4 Completed - Thailand ... More >> Faculty of Tropical Medicine, Mahidol University Bangkok, Thailand, 10400 Less <<
NCT02333890 Breast Cancer ... More >> Invasive Breast Cancer Less << Phase 2 Unknown March 2018 Canada, Ontario ... More >> The Ottawa Hospital Woman's Breast Health Centre Recruiting Ottawa, Ontario, Canada Contact: Angel Arnaout, Dr.    613-798-5555       Principal Investigator: Angel Arnaout, Dr. Less <<
NCT01103713 Asymptomatic Parasitemia In Pr... More >>egnancy Less << Phase 3 Terminated(See termination rea... More >>son in detailed description.) Less << - Benin ... More >> Centre de Sante d'AHOUANSORI -AGUE Cotonou, Benin Hôpital Bethesda Cotonou, Benin Kenya Siaya District Hospital Siaya, Kenya Malawi Zomba Central Hospital Zomba, Malawi Tanzania Teule Hospital Muheza, Tanga, Tanzania National Institute for Medical Research (Mwanza Centre)/ Nyamagana District Hospital Mwanza, Tanzania, 1903 Uganda Mulanda Health Centre IV Kampala, Uganda Less <<
NCT01708876 Uncomplicated Plasmodium Knowl... More >>esi Malaria Less << Phase 3 Completed - Malaysia ... More >> Kota Marudu District Hospital Kota Marudu, Sabah, Malaysia, 89108 Kudat District Hospital Kudat, Sabah, Malaysia, 89057 Pitas District Hospital Pitas, Sabah, Malaysia Less <<
NCT01784315 - Unknown December 2014 Bhutan ... More >> Vector Diseases Control Program, Gelephu Not yet recruiting Gelephu, Bhutan, 00975 Contact: Dr.Yeshey Dorjey    97517745239    yesheydorjey@yahoo.com    Contact: Dr.Kinley Penjor    97517619191    kalyx25@gmail.com    Principal Investigator: Tobgyel Drukpa          Sub-Investigator: Dr.Tashi Peldon          Sub-Investigator: Dr.Kinley Penjor          Vector Diseases Control Program, Gelephu Recruiting Gelephu, Bhutan, 00975 Contact: Dr.Yeshey Dorjey    97517745239    yesheydorjey@yahoo.com    Contact: Dr.Kinley Penjor    97517619191    kalyx25@gmail.com    Sub-Investigator: Tobgay Drukpa          Sub-Investigator: Dr.Tashi Peldon          Sub-Investigator: Dr.Kinley Penjor          Mr. Thinly Recruiting Sarpang, Bhutan, 00975 Contact: Yeshey Dorjey, MBBS    008801534689426    yesheydorjey@yahoo.com    Sub-Investigator: Dr. Kinly Penjor, MBBS Less <<
NCT01103713 - Terminated(See termination rea... More >>son in detailed description.) Less << - -
NCT01650558 HIV Not Applicable Active, not recruiting March 2019 Malawi ... More >> Blantyre Malaria Project Research Clinic Blantyre, Malawi Tisungane Clinic Zomba, Malawi Less <<
NCT00473837 Malaria Anaemia Not Applicable Completed - -
NCT01443130 - Completed - -
NCT01438177 - Terminated(PI left institution... More >>.) Less << - -
NCT00473837 - Completed - -
NCT00871156 Malaria Phase 1 Completed - United States, New York ... More >> GSK Investigational Site Buffalo, New York, United States, 14202 Less <<
NCT00308620 HIV Infections Phase 2 Phase 3 Terminated(Insufficient financ... More >>ial support; lack of efficacy for primary endpoint) Less << - United States, Minnesota ... More >> Minnesota ACTU Minneapolis, Minnesota, United States, 55455 Less <<
NCT01100060 Malaria Prophylaxis Phase 1 Completed - United States, Connecticut ... More >> Pfizer Investigational Site New Haven, Connecticut, United States, 06511 Less <<
NCT00308620 - Terminated(Insufficient financ... More >>ial support; lack of efficacy for primary endpoint) Less << - -
NCT02118090 Vivax Malaria Phase 4 Completed - Cambodia ... More >> Provincial Hospital Ban Lung, Rattanakiri, Cambodia Less <<
NCT01078779 Influenza Phase 2 Unknown August 2010 Singapore ... More >> Investigational Medicines Unit, National University Hospital Singapore, Singapore, 119074 Less <<
NCT02001012 Uncomplicated Knowlesi Malaria Phase 3 Completed - Malaysia ... More >> Kota Marudu District Hospital Kota Marudu, Sabah, Malaysia Kudat District Hospital Kudat, Sabah, Malaysia, 89057 Pitas District Hospital Pitas, Sabah, Malaysia Less <<
NCT01777477 Pancreatic Cancer Phase 1 Completed - Switzerland ... More >> University Hospital Zurich, Department of Oncology Zurich, ZH, Switzerland, 8091 Less <<
NCT01727531 Brain Metastasis COMPLETED 2025-08-13 Lankenau Medical Center, Wynne... More >>wood, Pennsylvania, 19096, United States Less <<
NCT01785979 Hyper-reactive Malarial Spleno... More >>megaly Malaria Anaemia Less << Phase 3 Withdrawn(Lack of funding) February 2017 Papua New Guinea ... More >> Lihir medical Centre Londolovit, New ireland province, Papua New Guinea Less <<
NCT02378532 Glioblastoma Multiforme Phase 1 Recruiting June 2019 Netherlands ... More >> Maastricht Radiation Oncology Recruiting Maastricht, Netherlands, 6202 AZ Less <<
NCT00844207 Malaria Phase 1 Completed - United States, Connecticut ... More >> Pfizer Investigational Site New Haven, Connecticut, United States, 06511 Less <<
NCT02932007 Atrial Fibrillation Phase 2 Recruiting September 2019 United States, Florida ... More >> University of South Florida Recruiting Tampa, Florida, United States, 33606 Contact: Nhi Tran, MS    813-259-0628    nntran@health.usf.edu    Contact: Jacob Siddoway       jsiddoway@health.usf.edu    Principal Investigator: Sami Noujaim, PhD          Sub-Investigator: Bengt Herweg, MD          Sub-Investigator: Dany Sayad, MD Less <<
NCT00972725 AIDS Phase 2 Completed - Belgium ... More >> GSK Investigational Site Gent, Belgium, 9000 Less <<
NCT01716260 - Completed - Bhutan ... More >> Vector Diseases Control Program Gelephu, Bhutan Less <<
NCT02071537 Malignant Neoplasm ... More >> Solid Tumors Less << Phase 1 Recruiting December 2018 United States, Ohio ... More >> University of Cincinnati Cancer Institute Recruiting Cincinnati, Ohio, United States, 45267-0502 Principal Investigator: Nagla Karim, MD, PhD          Sub-Investigator: Johm Morris, MD          Sub-Investigator: Sadia Benzaquin, MD          Sub-Investigator: Pankaj Desai, MS, PhD          Sub-Investigator: James Driscol, MD          Sub-Investigator: Ahmed Khaled, MD          Sub-Investigator: Jun Ying, PhD Less <<
NCT01814423 Malaria Phase 4 Completed - Guinea-Bissau ... More >> Projecto de Saúde de Bandim Bissau, Guinea-Bissau, 1004 Less <<
NCT03687905 - Recruiting September 30, 2019 Egypt ... More >> Fatma Gheet Recruiting Tanta, Egypt Contact: Fatma S Gheet, M.B.,BCh    +201148157993    fatmagheet@gmail.com Less <<
NCT02610686 Plasmodium Vivax Phase 4 Unknown December 2016 Vietnam ... More >> Chu R Cam Recruiting Pleiku, Gia Lai, Vietnam Contact: Phuc Bui, MD, PhD    +84 913522874    phucnimpe@yahoo.com    Contact: Hong Nguyen, MD    +84 01668188919    nvhong1982@yahoo.com    Sub-Investigator: Annette Erhart, MD, PhD          Sub-Investigator: Edu Rovira Vallbona, PhD Less <<
NCT02004314 HIV Not Applicable Completed - Canada, Quebec ... More >> Montreal Chest Institute, McGill University Health Centre Montreal, Quebec, Canada, H3A1A1 Less <<
NCT01546961 Vivax Malaria Not Applicable Active, not recruiting September 2019 Thailand ... More >> Shoklo Malaria Research Unit Tak, Mae Sot, Thailand, 63110 Less <<
NCT02463331 Autoimmune Hepatitis Phase 4 Completed - -
NCT02463331 - Completed - -
NCT01023477 Carcinoma, Intraductal, Noninf... More >>iltrating DCIS Ductal Carcinoma In Situ Less << Phase 1 Phase 2 Completed - United States, Virginia ... More >> Medical Oncology and Hematology Associates of Northern Virginia Fairfax, Virginia, United States, 22031 Virginia Cancer Specialists, PC Fairfax, Virginia, United States, 22031 Virginia Surgery Associates Fairfax, Virginia, United States, 22033 Inova Fairfax Hospital Falls Church, Virginia, United States, 22042 Less <<
NCT00969306 Small Cell Lung Cancer Phase 1 Completed - Netherlands ... More >> NKI/AvL Amsterdam, Netherlands VU Medical Center Amsterdam, Netherlands Maastricht Radiation Oncology Maastricht, Netherlands Maastricht University Medical Center Maastricht, Netherlands Less <<
NCT00972725 - Completed - -
NCT01575782 Small Cell Lung Cancer Phase 1 Terminated(Poor accrual) - Netherlands ... More >> MAASTRO clinic Maastricht, Limburg, Netherlands, 6229 ET Less <<
NCT02691910 Malaria, Vivax Phase 2 Phase 3 Completed - Brazil ... More >> Oswaldo Cruz Foundation Rio de Janeiro, Brazil, 21040-360 Institute of Biomedical Sciences, University of Sao Paulo São Paulo, Brazil, 05508-900 Less <<
NCT01894633 Brain Metastasis Phase 2 Terminated(terminated) - Mexico ... More >> Instituto Nacional de Cancerologia Mexico DF, DF, Mexico, 14080 Less <<
NCT01980745 Hepatitis, Autoimmune Phase 4 Completed - Brazil ... More >> University of São Paulo School of Medicine Sao Paulo, Brazil, 05403-010 Less <<
NCT02698748 Malaria Phase 2 Phase 3 Completed - Mozambique ... More >> Centro de Investigaçao em Saude de Manhiça Manhiça, Maputo, Mozambique, 1902 Less <<
NCT02496741 Glioma Cholan... More >>giocarcinoma Chondrosarcoma Less << Phase 1 Phase 2 Unknown December 2016 Netherlands ... More >> VU University Medical Center Not yet recruiting Amsterdam, Noord-Holland, Netherlands, 1081 HZ Contact: Myra E Van Linde, M.D.    +31(20)4441412    m.vanlinde@vumc.nl    Academic Medical Center Recruiting Amsterdam, Noord-Holland, Netherlands, 1105AZ Contact: Hanneke W Wilmink, M.D., Ph.D.    +31(20)5662895    j.w.wilmink@amc.uva.nl    Contact: Remco J Molenaar, M.Sc.    +31(20)5668587    r.j.molenaar@amc.nl    Principal Investigator: Hanneke W Wilmink, M.D., Ph.D.          Leiden University Medical Center Not yet recruiting Leiden, Zuid-Holland, Netherlands, 2333 ZA Contact: Hans J Gelderblom, M.D., Ph.D.    +31(71)5269111    A.J.Gelderblom@lumc.nl Less <<
NCT04323527 SARS-CoV Infection|Severe Acut... More >>e Respiratory Syndrome (SARS) Pneumonia Less << PHASE2 COMPLETED 2020-06-07 Hospital e Pronto Socorro Delp... More >>hina Rinaldi Abdel Aziz, Manaus, Amazonas, 69093-415, Brazil Less <<
NCT04328493 SARS-CoV-2 Infection|COVID-19 PHASE2 COMPLETED 2020-09-10 National Hospital for Tropical... More >> Diseases, Hanoi, Vietnam|Can Gio COVID Hospital, Ho Chi Minh City, Vietnam|Cho Ray Hospital, Ho Chi Minh City, Vietnam|Cu Chi COVID Hospital, Ho Chi Minh City, Vietnam|Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam Less <<
NCT04443270 COVID-19 PHASE1 UNKNOWN 2021-01-31 Centro Médico Nacional "20 de ... More >>Noviembre", Mexico City, Benito Juárez, 03229, Mexico Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.94mL

0.39mL

0.19mL

9.69mL

1.94mL

0.97mL

19.39mL

3.88mL

1.94mL

References

 

Historical Records

Categories